Pentixapharm
Pentixapharm is a clinical-stage German radiopharmaceutical biotech developing first-in-class CXCR4-targeted theranostic agents (PentixaFor for PET/CT diagnosis, PentixaTher for therapy) to address primary aldosteronism and hematological cancers, serving hospitals, cancer centers, and imaging centers via radiopharmacy distribution networks.
- Company typePublic
- Founded2024
- HeadquartersWürzburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pentixapharm does
Pentixapharm Holding AG is a clinical-stage radiopharmaceutical biotechnology company headquartered in Berlin, Germany, with a secondary office in Würzburg. Founded in 2019 and spun off from the Eckert & Ziegler Group, the company listed on the Frankfurt Stock Exchange Prime Standard (ticker: PTP) in October 2024 and is led by CEO Dr. Dirk Pleimes. Pentixapharm develops first-in-class CXCR4-targeted radiopharmaceuticals comprising a theranostic pair: [68Ga]Ga-PentixaFor, a gallium-68-labeled diagnostic used in PET/CT imaging, and [177Lu]Lu-PentixaTher / [90Y]Y-PentixaTher, therapeutic agents labeled with lutetium-177 or yttrium-90 for targeted radiotherapy. The lead clinical program is the FDA IND-cleared Phase 3 PANDA trial evaluating PentixaFor for non-invasive diagnosis of primary aldosteronism in approximately 270 patients, with FDA 'Study May Proceed' also secured for the PENTHERA Phase I/II trial in hemato-oncology (AML and multiple myeloma). A second platform, GT-008, targets CD24 with a glycan-dependent antibody radiopharmaceutical, acquired via the July 2024 purchase of Glycotope GmbH's target discovery business.
The company's commercial model is sales-led through radiopharmacy networks, imaging-company partnerships, and US-based commercial partners, targeting hospitals, cancer centers, and imaging centers with PET/CT infrastructure. Pentixapharm is pre-revenue from product sales, with LTM revenue of approximately $460,000 and €117 thousand for Q1-Q3 2025 likely reflecting minor licensing or collaboration receipts. Following an October 2025 organizational restructuring that reduced headcount at Pentixapharm AG by approximately 50% to roughly 80 employees (with over 80% focused on R&D), the company is concentrating resources on its late-stage clinical programs. Critical supply chain and manufacturing relationships include Eckert & Ziegler for isotope supply and ARRONAX (CHU Nantes) for radiopharmaceutical manufacturing, with clinical research conducted through the University Hospital of Nantes.
The company is funded through a combination of public equity and a planned 2026 rights-issue capital increase of up to €20 million, with major shareholder Eckert Wagniskapital und Frühphasenfinanzierung GmbH (~36% stake) committed to full subscription. BankM AG initiated coverage in June 2026 with a Buy rating and a €12.61 fair-value target. A BaFin financial reporting enforcement review of the 2024 consolidated financial statements is underway, with preliminary findings questioning EUR 34.7 million in intangible asset valuations, representing a governance overhang during a pivotal Phase 3 execution period.
Pentixapharm firmographics
Firmographics- Name
- Pentixapharm
- Legal name
- Pentixapharm Holding AG
- Website
- https://pentixapharm.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pentixapharm is a clinical-stage German radiopharmaceutical biotech developing first-in-class CXCR4-targeted theranostic agents (PentixaFor for PET/CT diagnosis, PentixaTher for therapy) to address primary aldosteronism and hematological cancers, serving hospitals, cancer centers, and imaging centers via radiopharmacy distribution networks.
- Ownership category
- akta.pro rank
Pentixapharm industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
Keywords
Where Pentixapharm is headquartered
LocationHeadquarters
- HQ city
- Würzburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Pentixapharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Radiopharmaceutical Product Sales: Pre-revenue clinical-stage biotech. Future revenue expected from sales of radiopharmaceutical products through radiopharmacy networks upon regulatory approval. Potential licensing and partnership revenues.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Pentixapharm product offering
Product offeringCore offering
Pentixapharm is a clinical-stage biotech developing a CXCR4-targeted theranostic radiopharmaceutical pair: PentixaFor, a gallium-68 labeled diagnostic for PET/CT imaging (notably for non-invasive subtyping of primary aldosteronism), and PentixaTher, a lutetium-177 or yttrium-90 labeled therapeutic for CXCR4-expressing hematological malignancies. The portfolio also includes the GT-008 glycan-dependent anti-CD24 antibody radiopharmaceutical for solid tumors and a broader CXCR4 imaging platform.
Product overview
Pentixapharm is a clinical-stage biotech developing a portfolio of radiopharmaceuticals anchored by its CXCR4-targeted theranostic platform. The core products include [68Ga]Ga-PentixaFor (diagnostic PET/CT imaging agent) and [177Lu]Lu-PentixaTher/[90Y]Y-PentixaTher (therapeutic radiopharmaceuticals). The company has expanded into glycan-dependent antibody-based radiopharmaceuticals through the GT-008 program targeting CD24. The portfolio spans oncology (hematological cancers, solid tumors) and cardiology (primary aldosteronism diagnosis), with Phase 3 PANDA trial ongoing for cardiovascular diagnostic and Phase I/II trials in hemato-oncology.
Differentiator
Problem solved
Functional benefit
Brands
- PentixaFor: CXCR4-targeted gallium-68-labeled radiodiagnostic for PET/CT imaging, used in primary aldosteronism diagnosis and theranostic pairing
- PentixaTher
- GT-008
- CXCR4-Targeted Imaging Platform
Products and services
- [68Ga]Ga-PentixaFor
- [90Y]Y-PentixaTher
- [177Lu]Lu-PentixaTher
- GT-008
Companies that use Pentixapharm
Customer profileSegments3 records
Ideal customer profiles2 records
Pentixapharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pentixapharm partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Glycotope GmbHcoreAcquisition of Glycotope GmbH's target discovery business in July 2024, providing access to additional targeting technologies and expanding Pentixapharm's pipeline capabilities in radiopharmaceutical development.
- Eckert & ZieglercoreIsotope supply partnership for reliable sourcing of medical isotopes (gallium-68, lutetium-177, yttrium-90) required for radiopharmaceutical manufacturing. Critical supply chain partner.
- ARRONAX (CHU Nantes)coreManufacturing partnership with ARRONAX radiopharmacy at CHU Nantes for production of radiopharmaceutical products for clinical trials and eventual commercial supply.
- University Hospital of NantescoreClinical trial partnership for conducting studies on CXCR4-targeted radiopharmaceuticals. Provides clinical research capabilities, patient access, and scientific expertise for trial execution.
Scale indicators2 records
Recent moves8 records
Expansion highlights6 records
Pentixapharm competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pentixapharm social profiles
Digital presencePentixapharm compliance and trust
Trust signalCompliance1 record
Pentixapharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pentixapharm leadership team
Management profileNumber of profiles
Profiles5 records
Pentixapharm subsidiaries and ownership
Company hierarchySubsidiaries2 records
Pentixapharm funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pentixapharm M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pentixapharm
What does Pentixapharm do?
Pentixapharm is a clinical-stage biotech developing a CXCR4-targeted theranostic radiopharmaceutical pair: PentixaFor, a gallium-68 labeled diagnostic for PET/CT imaging (notably for non-invasive subtyping of primary aldosteronism), and PentixaTher, a lutetium-177 or yttrium-90 labeled therapeutic for CXCR4-expressing hematological malignancies. The portfolio also includes the GT-008 glycan-dependent anti-CD24 antibody radiopharmaceutical for solid tumors and a broader CXCR4 imaging platform.
Is Pentixapharm a public or private company?
Pentixapharm is a public company. It is classified as public and is currently operating.
When was Pentixapharm founded?
Pentixapharm was founded in 2024. It employs 11 to 50 people.
Where is Pentixapharm based?
Pentixapharm is headquartered in Würzburg, Germany, in the Europe region.
How does Pentixapharm make money?
One revenue line is on record: radiopharmaceutical Product Sales.
Does Pentixapharm have an API?
No public API is recorded for Pentixapharm.
What industry is Pentixapharm in?
Pentixapharm's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.